GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Electromed Inc (AMEX:ELMD) » Definitions » Altman Z-Score

Electromed (Electromed) Altman Z-Score

: 13.94 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 14.15 is strong.

Electromed has a Altman Z-Score of 13.94, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Electromed's Altman Z-Score or its related term are showing as below:

ELMD' s Altman Z-Score Range Over the Past 10 Years
Min: 3.02   Med: 10.45   Max: 29.39
Current: 14.15

During the past 13 years, Electromed's highest Altman Z-Score was 29.39. The lowest was 3.02. And the median was 10.45.


Electromed Altman Z-Score Historical Data

The historical data trend for Electromed's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Electromed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.20 29.39 15.00 9.39 9.45

Electromed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.52 10.97 9.45 12.03 11.43

Competitive Comparison

For the Medical Devices subindustry, Electromed's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Electromed Altman Z-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Electromed's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Electromed's Altman Z-Score falls into.



Electromed Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Electromed's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.6961+1.4*0.4391+3.3*0.1136+0.6*18.3618+1.0*1.1007
=13.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $46.96 Mil.
Total Current Assets was $39.27 Mil.
Total Current Liabilities was $6.57 Mil.
Retained Earnings was $20.62 Mil.
Pre-Tax Income was 2.359 + 0.219 + 1.535 + 1.222 = $5.34 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Revenue was 13.689 + 12.324 + 13.612 + 12.068 = $51.69 Mil.
Market Cap (Today) was $121.59 Mil.
Total Liabilities was $6.62 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(39.265 - 6.573)/46.964
=0.6961

X2=Retained Earnings/Total Assets
=20.622/46.964
=0.4391

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(5.335 - 0)/46.964
=0.1136

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=121.592/6.622
=18.3618

X5=Revenue/Total Assets
=51.693/46.964
=1.1007

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Electromed has a Altman Z-Score of 13.94 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Electromed  (AMEX:ELMD) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Electromed Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Electromed's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Electromed (Electromed) Business Description

Traded in Other Exchanges
N/A
Address
500 Sixth Avenue NW, New Prague, MN, USA, 56071
Electromed Inc is a United States-based company that develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Executives
Andrew Summers director 601 JEFFERSON STREET, HOUSTON TX 77002
James L. Cunniff director, officer: CEO and President 500 SIXTH AVE NW, NEW PRAGUE MN 56071
Kathleen Skarvan officer: Chief Executive Officer 40 WEST HIGHLAND PARK DR NE, HUTCHINSON MN 55350
Bradley M. Nagel officer: Chief Financial Officer 500 SIXTH AVE NW, NEW PRAGUE MN 56071
Michelle C. Wirtz officer: Chief Financial Officer 500 SIXTH AVENUE NW,, NEW PRAGUE MN 56071
Christopher G. Holland officer: Chief Commercial Officer 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Joseph L. Galatowitsch director 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Kathleen A Tune director 60 SOUTH SIXTH STREET, SUITE 3620, MINNEAPOLIS MN 55402
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Stephen H. Craney director 25340 SANDPIPER LANE, WINONA MN 55987
Andrea M. Walsh director 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
George H. Winn director 27451 COUNTRY HOLLOWS LANE, NEW PRAGUE MN 56701
Michael Joseph Maccourt officer: Chief Financial Officer 500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Gregory Fluet director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
John L Erb director C/O VASCULAR SOLUTIONS, INC., 6464 SYCAMORE COURT N., MINNEAPOLIS, MN 55369

Electromed (Electromed) Headlines

From GuruFocus

Sidoti Virtual Microcap Investor Conference

By ACCESSWIRE ACCESSWIRE 11-19-2020

Electromed Stock Appears To Be Significantly Overvalued

By GF Value GF Value 06-06-2021